Drugs / BI 1831169
BI 1831169
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07176975 | Aug 2027 → Dec 2028 | cancer | Boehringer Ingelheim | Suspended | No outcome recorded |
| Phase 1 | NCT05155332 | Mar 2022 → Dec 2027 | cancer | Boehringer Ingelheim | Suspended | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 1831169 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07176975 ↗ |
| Known as | Vesicular stomatitis virus (VSV)-glycoprotein | “Vesicular stomatitis virus (VSV)-glycoprotein (GP; BI 1831169)” PMID 35699077 ↗ Jun 2022 |
| Known as | VSV-GP | “VSV-GP (BI 1831169)” PMID 35699077 ↗ Jun 2022 |
| Modality | Other / unclassified | “This live, recombinant oncolytic virus” PMID 35699077 ↗ Jun 2022 |
| Route | Other | “an injection into the tumor” NCT05155332 ↗ |